The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of biweekly gemcitabine, paclitaxel, and bevacizumab as frontline therapy for metastatic breast cancer (MBC).
Z. A. Nahleh
Honoraria - Lilly
Research Funding - Genentech; Lilly
R. Gupta
No relevant relationships to disclose
J. Abrams
No relevant relationships to disclose
E. M. Gartner
No relevant relationships to disclose
L. Reichle
No relevant relationships to disclose